Symbols / AMGN Stock $346.25 +2.43% Amgen Inc.

Healthcare • Drug Manufacturers - General • United States • NMS
AMGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Robert A. Bradway
Exch · Country NMS · United States
Market Cap 186.87B
Enterprise Value 232.96B
Income 7.71B
Sales 36.75B
FCF (ttm) 7.50B
Book/sh 16.07
Cash/sh 16.93
Employees 31,500
Insider 10d —
IPO Jun 17, 1983
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 67.22%
P/E 24.33
Forward P/E 14.82
PEG —
P/S 5.08
P/B 21.55
P/C —
EV/EBITDA 14.02
EV/Sales 6.34
Quick Ratio 0.73
Current Ratio 1.14
Debt/Eq 640.27
LT Debt/Eq —
EPS (ttm) 14.23
EPS next Y 23.36
EPS Growth 112.10%
Revenue Growth 8.60%
EPS Gr Q/Q 112.60%
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-04-30
ROA 7.93%
ROE 106.10%
ROIC —
Gross Margin 70.78%
Oper. Margin 30.55%
Profit Margin 20.98%
Shs Outstand 539.69M
Shs Float 537.62M
Insider Own 0.22%
Instit Own 85.21%
Short Float 2.37%
Short Ratio 4.66
Short Interest 12.74M
52W High 391.29
vs 52W High -11.51%
52W Low 261.43
vs 52W Low 32.44%
Beta 0.47
Impl. Vol. 0.78%
Rel Volume 1.30
Avg Volume 2.73M
Volume 3.55M
Target (mean) $352.73
Tgt Median $353.00
Tgt Low $200.00
Tgt High $432.00
# Analysts 30
Recom Hold
Prev Close $338.02
Price $346.25
Change 2.43%
About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$352.73
Mean price target
2. Current target
$346.25
Latest analyst target
3. DCF / Fair value
$250.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$346.25
Low
$200.00
High
$432.00
Mean
$352.73

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 init Canaccord Genuity — → Hold $366
2026-04-13 main UBS Buy → Buy $400
2026-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $326
2026-04-09 main Guggenheim Neutral → Neutral $351
2026-04-08 reit Cantor Fitzgerald Neutral → Neutral $350
2026-03-10 init Jefferies — → Hold $350
2026-02-20 init Barclays — → Equal-Weight $350
2026-02-19 main Wells Fargo Equal-Weight → Equal-Weight $375
2026-02-18 main Piper Sandler Overweight → Overweight $432
2026-02-12 down Freedom Broker Buy → Hold $375
2026-02-06 main Argus Research Buy → Buy $400
2026-02-06 main Guggenheim Neutral → Neutral $347
2026-02-04 main Citigroup Neutral → Neutral $345
2026-02-04 main Morgan Stanley Equal-Weight → Equal-Weight $309
2026-02-04 main Cantor Fitzgerald Neutral → Neutral $350
2026-02-04 main Leerink Partners Outperform → Outperform $355
2026-01-26 main UBS Buy → Buy $390
2026-01-20 down Bernstein Outperform → Market Perform $335
2026-01-08 main Truist Securities Hold → Hold $319
2025-12-12 main Morgan Stanley Equal-Weight → Equal-Weight $304
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 BRADWAY ROBERT A Chief Executive Officer — 119,782 $156.35 $18,727,916
2026-03-03 GORDON MURDO Officer — 13,403 $0.00 $0
2026-03-03 SANTOS ESTEBAN Officer — 11,259 $0.00 $0
2026-03-03 REESE DAVID M. Chief Technology Officer — 12,063 $0.00 $0
2026-03-03 GRIFFITH PETER H. Chief Financial Officer — 12,063 $0.00 $0
2026-03-03 GRYGIEL NANCY A Officer — 2,010 $0.00 $0
2026-03-03 KHOSLA RACHNA Officer — 1,876 $0.00 $0
2026-03-03 MILLER DEREK Officer — 3,484 $0.00 $0
2026-03-03 BUSCH MATTHEW C. Officer — 938 $0.00 $0
2026-03-03 BRADWAY ROBERT A Chief Executive Officer — 42,657 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
36,751.00
+9.95%
33,424.00
+18.57%
28,190.00
+7.09%
26,323.00
Operating Revenue
35,148.00
+9.75%
32,026.00
+19.01%
26,910.00
+8.50%
24,801.00
Cost Of Revenue
12,037.00
-6.39%
12,858.00
+52.15%
8,451.00
+31.92%
6,406.00
Reconciled Cost Of Revenue
12,037.00
-6.39%
12,858.00
+52.15%
8,451.00
+31.92%
6,406.00
Gross Profit
24,714.00
+20.17%
20,566.00
+4.19%
19,739.00
-0.89%
19,917.00
Operating Expense
15,634.00
+17.48%
13,308.00
+12.38%
11,842.00
+14.40%
10,351.00
Research And Development
7,272.00
+21.93%
5,964.00
+24.67%
4,784.00
+7.89%
4,434.00
Selling General And Administration
7,050.00
-0.65%
7,096.00
+14.84%
6,179.00
+14.13%
5,414.00
Other Operating Expenses
1,312.00
+429.03%
248.00
-71.79%
879.00
+74.75%
503.00
Total Expenses
27,671.00
+5.75%
26,166.00
+28.94%
20,293.00
+21.10%
16,757.00
Operating Income
9,080.00
+25.10%
7,258.00
-8.09%
7,897.00
-17.45%
9,566.00
Total Operating Income As Reported
9,080.00
+25.10%
7,258.00
-8.09%
7,897.00
-17.45%
9,566.00
EBITDA
16,898.00
+26.52%
13,356.00
-9.76%
14,801.00
+21.63%
12,169.00
Normalized EBITDA
16,898.00
+26.52%
13,356.00
-9.76%
14,801.00
+21.63%
12,169.00
Reconciled Depreciation
5,167.00
-7.60%
5,592.00
+37.36%
4,071.00
+19.14%
3,417.00
EBIT
11,731.00
+51.09%
7,764.00
-27.64%
10,730.00
+22.60%
8,752.00
Total Unusual Items
—
—
0.00
0.00
Total Unusual Items Excluding Goodwill
—
—
0.00
0.00
Special Income Charges
—
—
0.00
0.00
Other Special Charges
—
—
—
—
Net Income
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Pretax Income
8,976.00
+94.75%
4,609.00
-41.32%
7,855.00
+6.93%
7,346.00
Net Non Operating Interest Income Expense
-2,755.00
+12.68%
-3,155.00
-9.74%
-2,875.00
-104.48%
-1,406.00
Interest Expense Non Operating
2,755.00
-12.68%
3,155.00
+9.74%
2,875.00
+104.48%
1,406.00
Net Interest Income
-2,755.00
+12.68%
-3,155.00
-9.74%
-2,875.00
-104.48%
-1,406.00
Interest Expense
2,755.00
-12.68%
3,155.00
+9.74%
2,875.00
+104.48%
1,406.00
Other Income Expense
2,651.00
+423.91%
506.00
-82.14%
2,833.00
+448.03%
-814.00
Other Non Operating Income Expenses
2,651.00
+423.91%
506.00
-82.14%
2,833.00
+448.03%
-814.00
Tax Provision
1,265.00
+143.74%
519.00
-54.39%
1,138.00
+43.32%
794.00
Tax Rate For Calcs
0.00
+25.15%
0.00
-22.34%
0.00
+34.26%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Net Income From Continuing Operation Net Minority Interest
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Net Income From Continuing And Discontinued Operation
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Net Income Continuous Operations
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Normalized Income
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Net Income Common Stockholders
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Diluted EPS
14.23
+88.23%
7.56
-39.47%
12.49
+3.14%
12.11
Basic EPS
14.33
+88.06%
7.62
-39.33%
12.56
+3.12%
12.18
Basic Average Shares
538.00
+0.19%
537.00
+0.37%
535.00
-0.56%
538.00
Diluted Average Shares
542.00
+0.18%
541.00
+0.56%
538.00
-0.55%
541.00
Diluted NI Availto Com Stockholders
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Line Item Trend 2023-12-31
Total Assets
97,154.00
Current Assets
30,332.00
Cash Cash Equivalents And Short Term Investments
10,944.00
Cash And Cash Equivalents
10,944.00
Other Short Term Investments
0.00
Receivables
7,942.00
Accounts Receivable
7,268.00
Taxes Receivable
172.00
Inventory
9,518.00
Raw Materials
993.00
Work In Process
5,747.00
Finished Goods
2,778.00
Prepaid Assets
1,647.00
Other Current Assets
281.00
Total Non Current Assets
66,822.00
Net PPE
5,941.00
Gross PPE
15,749.00
Accumulated Depreciation
-9,808.00
Properties
0.00
Land And Improvements
339.00
Buildings And Improvements
4,507.00
Machinery Furniture Equipment
4,540.00
Construction In Progress
1,550.00
Other Properties
4,813.00
Goodwill And Other Intangible Assets
51,270.00
Goodwill
18,629.00
Other Intangible Assets
32,641.00
Other Non Current Assets
9,611.00
Total Liabilities Net Minority Interest
90,922.00
Current Liabilities
18,392.00
Payables And Accrued Expenses
15,568.00
Payables
4,459.00
Accounts Payable
1,590.00
Dividends Payable
1,205.00
Current Accrued Expenses
11,109.00
Pensionand Other Post Retirement Benefit Plans Current
1,381.00
Total Tax Payable
1,664.00
Income Tax Payable
1,664.00
Current Debt And Capital Lease Obligation
1,443.00
Current Debt
1,443.00
Total Non Current Liabilities Net Minority Interest
72,530.00
Long Term Debt And Capital Lease Obligation
63,170.00
Long Term Debt
63,170.00
Tradeand Other Payables Non Current
4,680.00
Non Current Deferred Liabilities
2,354.00
Non Current Deferred Taxes Liabilities
2,354.00
Other Non Current Liabilities
2,326.00
Stockholders Equity
6,232.00
Common Stock Equity
6,232.00
Capital Stock
33,070.00
Common Stock
33,070.00
Share Issued
535.40
Ordinary Shares Number
535.40
Treasury Shares Number
0.00
Retained Earnings
-26,549.00
Gains Losses Not Affecting Retained Earnings
-289.00
Other Equity Adjustments
9.00
Total Equity Gross Minority Interest
6,232.00
Total Capitalization
69,402.00
Working Capital
11,940.00
Invested Capital
70,845.00
Total Debt
64,613.00
Net Debt
53,669.00
Net Tangible Assets
-45,038.00
Tangible Book Value
-45,038.00
Current Provisions
—
Duefrom Related Parties Current
502.00
Foreign Currency Translation Adjustments
-298.00
Interest Payable
936.00
Unrealized Gain Loss
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
9,958.00
-13.33%
11,490.00
+35.64%
8,471.00
-12.86%
9,721.00
Cash Flow From Continuing Operating Activities
9,958.00
-13.33%
11,490.00
+35.64%
8,471.00
-12.86%
9,721.00
Net Income From Continuing Operations
7,711.00
+88.53%
4,090.00
-39.11%
6,717.00
+2.52%
6,552.00
Depreciation Amortization Depletion
5,167.00
-7.60%
5,592.00
+37.36%
4,071.00
+19.14%
3,417.00
Depreciation
5,167.00
-7.60%
5,592.00
+37.36%
4,071.00
+19.14%
3,417.00
Depreciation And Amortization
5,167.00
-7.60%
5,592.00
+37.36%
4,071.00
+19.14%
3,417.00
Other Non Cash Items
149.00
+184.18%
-177.00
+36.10%
-277.00
+8.58%
-303.00
Stock Based Compensation
494.00
-6.79%
530.00
+22.97%
431.00
+7.48%
401.00
Asset Impairment Charge
1,200.00
+654.72%
159.00
-81.32%
851.00
—
Deferred Tax
-721.00
+41.29%
-1,228.00
+3.53%
-1,273.00
-6.26%
-1,198.00
Deferred Income Tax
-721.00
+41.29%
-1,228.00
+3.53%
-1,273.00
-6.26%
-1,198.00
Operating Gains Losses
-2,064.00
-1398.11%
159.00
+110.16%
-1,565.00
-198.74%
1,585.00
Gain Loss On Investment Securities
-2,064.00
-1398.11%
159.00
+110.16%
-1,565.00
-1332.28%
127.00
Change In Working Capital
-1,978.00
-183.64%
2,365.00
+588.64%
-484.00
+33.97%
-733.00
Change In Receivables
-2,676.00
-706.80%
441.00
+143.45%
-1,015.00
-36.06%
-746.00
Changes In Account Receivables
-2,676.00
-706.80%
441.00
+143.45%
-1,015.00
-36.06%
-746.00
Change In Inventory
886.00
-65.01%
2,532.00
+415.68%
491.00
+166.17%
-742.00
Change In Payables And Accrued Expense
736.00
+24433.33%
3.00
+102.36%
-127.00
-118.70%
679.00
Change In Accrued Expense
2,065.00
+72.95%
1,194.00
+27.70%
935.00
-0.85%
943.00
Change In Payable
-1,329.00
-11.59%
-1,191.00
-12.15%
-1,062.00
-302.27%
-264.00
Change In Account Payable
428.00
+37.18%
312.00
+177.61%
-402.00
-361.04%
154.00
Change In Other Working Capital
499.00
+442.39%
92.00
-90.35%
953.00
—
Change In Other Current Assets
-1,267.00
-94.33%
-652.00
-15.60%
-564.00
-318.60%
258.00
Change In Other Current Liabilities
-156.00
-205.88%
-51.00
+77.03%
-222.00
-21.98%
-182.00
Investing Cash Flow
-1,943.00
-85.76%
-1,046.00
+96.01%
-26,204.00
-333.55%
-6,044.00
Cash Flow From Continuing Investing Activities
-1,943.00
-85.76%
-1,046.00
+96.01%
-26,204.00
-333.55%
-6,044.00
Net PPE Purchase And Sale
-1,858.00
-69.53%
-1,096.00
+1.44%
-1,112.00
-18.80%
-936.00
Purchase Of PPE
-1,858.00
-69.53%
-1,096.00
+1.44%
-1,112.00
-18.80%
-936.00
Capital Expenditure
-1,858.00
-69.53%
-1,096.00
+1.44%
-1,112.00
-18.80%
-936.00
Net Investment Purchase And Sale
0.00
0.00
-100.00%
1,673.00
+222.21%
-1,369.00
Purchase Of Investment
—
0.00
+100.00%
-1.00
+99.96%
-2,587.00
Sale Of Investment
0.00
0.00
-100.00%
1,673.00
+37.36%
1,218.00
Net Business Purchase And Sale
-53.00
0.00
+100.00%
-26,989.00
-603.02%
-3,839.00
Purchase Of Business
-53.00
0.00
+100.00%
-26,989.00
-603.02%
-3,839.00
Gain Loss On Sale Of Business
—
0.00
0.00
-100.00%
567.00
Net Other Investing Changes
-32.00
-164.00%
50.00
-77.68%
224.00
+124.00%
100.00
Financing Cash Flow
-10,859.00
-15.34%
-9,415.00
-144.73%
21,048.00
+621.38%
-4,037.00
Cash Flow From Continuing Financing Activities
-10,859.00
-15.34%
-9,415.00
-144.73%
21,048.00
+621.38%
-4,037.00
Net Issuance Payments Of Debt
-5,000.00
-38.89%
-3,600.00
-113.68%
26,323.00
+280.45%
6,919.00
Issuance Of Debt
0.00
0.00
-100.00%
27,777.00
+301.46%
6,919.00
Repayment Of Debt
-5,000.00
-38.89%
-3,600.00
-147.59%
-1,454.00
0.00
Long Term Debt Issuance
0.00
0.00
-100.00%
27,777.00
+301.46%
6,919.00
Long Term Debt Payments
-5,000.00
-38.89%
-3,600.00
-147.59%
-1,454.00
0.00
Net Long Term Debt Issuance
-5,000.00
-38.89%
-3,600.00
-113.68%
26,323.00
+280.45%
6,919.00
Net Common Stock Issuance
0.00
+100.00%
-200.00
0.00
+100.00%
-6,360.00
Common Stock Payments
0.00
+100.00%
-200.00
0.00
+100.00%
-6,360.00
Common Stock Dividend Paid
-5,124.00
-6.04%
-4,832.00
-6.06%
-4,556.00
-8.58%
-4,196.00
Cash Dividends Paid
-5,124.00
-6.04%
-4,832.00
-6.06%
-4,556.00
-8.58%
-4,196.00
Repurchase Of Capital Stock
0.00
+100.00%
-200.00
0.00
+100.00%
-6,360.00
Net Other Financing Charges
-735.00
+6.13%
-783.00
-8.90%
-719.00
-79.75%
-400.00
Changes In Cash
-2,844.00
-376.38%
1,029.00
-68.96%
3,315.00
+1020.83%
-360.00
Beginning Cash Position
11,973.00
+9.40%
10,944.00
+43.45%
7,629.00
-4.51%
7,989.00
End Cash Position
9,129.00
-23.75%
11,973.00
+9.40%
10,944.00
+43.45%
7,629.00
Free Cash Flow
8,100.00
-22.07%
10,394.00
+41.24%
7,359.00
-16.23%
8,785.00
Change In Income Tax Payable
-1,757.00
-16.90%
-1,503.00
-127.73%
-660.00
-57.89%
-418.00
Change In Tax Payable
-1,757.00
-16.90%
-1,503.00
-127.73%
-660.00
-57.89%
-418.00
Earnings Losses From Equity Investments
—
-10.00
-190.91%
11.00
-98.77%
891.00
Sale Of Business
—
—
—
130.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category